Percutaneous Ablation Versus Robotic Partial Nephrectomy in the Treatment of cT1b Renal Tumors: Oncologic and Functional Outcomes of a Propensity Score-weighted Analysis.


Journal

Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955

Informations de publication

Date de publication:
04 2020
Historique:
received: 11 05 2019
revised: 25 09 2019
accepted: 06 10 2019
pubmed: 27 1 2020
medline: 30 1 2021
entrez: 27 1 2020
Statut: ppublish

Résumé

The purpose of this study was to assess oncologic and functional outcomes of both percutaneous ablation (cryoablation and radiofrequency ablation) and robot-assisted partial nephrectomy (RAPN) in the treatment of renal tumors larger than 4 cm. We retrospectively analyzed prospectively collected data from 102 consecutive patients, who underwent minimally invasive treatment for cT1b renal tumors at our institution. Primary renal function outcome was assessed by estimated glomerular filtration rate preservation at baseline and 1 year postoperatively. Perioperative data and functional and oncologic outcome were collected. Multivariate regression models were used to compare functional outcomes between groups. Cancer-specific survival and recurrence-free survival were estimated at 2 years using the Kaplan-Meier method and compared with Cox proportional hazards regression model to calculate hazard ratios (HRs). To control for selection bias between the different treatments, we adjusted our models with an inverse probability of treatment weighting propensity score. There was no significant difference in renal preservation between the groups (P = .664). Multivariate analysis did not show a statistically significant difference in terms of renal function outcomes between the RAPN and percutaneous thermal ablation groups. The adjusted HR regarding the local recurrence-free survival was significantly shorter for the cryoablation group (HR, 4.3; 95% confidence interval, 1.78-10.37; P = .001). Our study demonstrated the equivalence between RAPN and percutaneous ablative techniques for the preservation of renal function in the treatment of T1b tumors. RAPN offers a better local control than percutaneous ablation, in terms of primary success rate.

Identifiants

pubmed: 31982346
pii: S1558-7673(19)30310-6
doi: 10.1016/j.clgc.2019.10.006
pii:
doi:

Substances chimiques

Creatinine AYI8EX34EU

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

138-147

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Gregory Rembeyo (G)

Department of Urology, HEGP, Paris, France; Université Paris Descartes, Faculté de Médecine, Paris, France. Electronic address: gregory.rembeyo@gmail.com.

Jean-Michel Correas (JM)

Université Paris Descartes, Faculté de Médecine, Paris, France; Department of Adult Radiology, Hôpital NECKER - Enfant Malades, Paris, France.

Rodolphe Jantzen (R)

Université Paris Descartes, Faculté de Médecine, Paris, France; Medical Informatics, Biostatistics and Public Health Department, HEGP, Paris, France.

François Audenet (F)

Department of Urology, HEGP, Paris, France; Université Paris Descartes, Faculté de Médecine, Paris, France.

Charles Dariane (C)

Department of Urology, HEGP, Paris, France; Université Paris Descartes, Faculté de Médecine, Paris, France.

Christophe Delavaud (C)

Université Paris Descartes, Faculté de Médecine, Paris, France; Department of Adult Radiology, Hôpital NECKER - Enfant Malades, Paris, France.

Arnaud Mejean (A)

Department of Urology, HEGP, Paris, France; Université Paris Descartes, Faculté de Médecine, Paris, France.

Marc-Olivier Timsit (MO)

Department of Urology, HEGP, Paris, France; Université Paris Descartes, Faculté de Médecine, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH